All Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Nerouology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers' and Babies Health. Clinical trials are an essential component of helathcare. They provide the evidence to evaluate the safety and efficacy of new treantments and diagnositics, and provide alternative treatment options for patients with unmet needs.
An oral treatment for Ulcerative Colitis
Study of GS-5290 in participants with moderately to severely active ulcerative colitis
Do you have gynaecological cancer with hormone receptor positive disease?
This trial is for people with gynaecological cancers whose tumours are potentially treatable with endocrine treatment.
Pefozafermin: Treatment for advanced fatty liver disease (cirrhosis)
Phenylketonuria (PKU): An early phase trial of a new treatment for PKU
This study is trialing a novel drug, called JNT-517, which works by increasing excretion of phenylalanine in the urine to reduce circulating levels in the blood.
Pilaster - New add on therapy to help treat chronic obstructive pulmonary disease with chronic bronchitis
Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis.
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures
PRECeDe Trial: Prevention of neonatal Respiratory distress with antenatal corticosteroids prior to Elective Caesarean section in women with diabetes – A Randomised Trial
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
PUERTA: A novel treatment for patients in acute respiratory distress
ALT-100-002: Pioneering the Utility of eNAMPT-Reducing Therapies in Acute Respiratory Distress Syndrome [ARDS]/ ventilator-induced lung injury.
Evaluating a new treatment for paediatric patients with ulcerative colitis.
The purpose of this study is to evaluate the effectiveness of guselkumab in pediatric participants with moderately to severely active ulcerative colitis through open label induction and through maintenance therapy among participants who were induction responders.